An automated solid-phase extraction (SPE) protocol followed by gas chromatography coupled with tandem mass spectrometry was developed for quantification of caffeine, cyamemazine, meprobamate, morphine and 6-monoacetylmorphine (6-MAM) in 11 biological matrices [blood, urine, bile, vitreous humor, liver, kidney, lung and skeletal muscle, brain, adipose tissue and bone marrow (BM)]. The assay was validated for linearity, within-and between-day precision and accuracy, limits of quantification, selectivity, extraction recovery (ER), sample dilution and autosampler stability on BM. For the other matrices, partial validation was performed (limits of quantification, linearity, within-day precision, accuracy, selectivity and ER). The lower limits of quantification were 12.5 ng/mL(ng/g) for 6-MAM, morphine and cyamemazine, 100 ng/mL(ng/g) for meprobamate and 50 ng/ mL(ng/g) for caffeine. Analysis of real-case samples demonstrated the performance of the assay in forensic toxicology to investigate challenging cases in which, for example, blood is not available or in which analysis in alternative matrices could be relevant. The SPE protocol was also assessed as an extraction procedure that could target other relevant analytes of interest. The extraction procedure was applied to 12 molecules of forensic interest with various physicochemical properties (alimemazine, alprazolam, amitriptyline, citalopram, cocaine, diazepam, levomepromazine, nordazepam, tramadol, venlafaxine, pentobarbital and phenobarbital). All drugs were able to be detected at therapeutic concentrations in blood and in the alternate matrices.
Introduction
In forensic toxicology, analyzing matrices (fluids and tissues) other than blood are widely agreed to be an important issue in various situations such as exsanguinations, putrefaction, postmortem redistribution, etc. (1) . Pharmacokinetic and toxicological data (distribution, accumulation, metabolism, toxic concentration, etc.) are necessary to improve the interpretation of analyte concentrations found. The reliability of data from experimental studies and routine analysis of real postmortem cases depends on assay performance, and more specifically on the limits of quantification, accuracy and precision. Advances in analytical technology, especially in the field of mass spectrometry, have significantly improved the specificity and sensitivity of drug detection in complex samples, matrix effects; however, they remain an acknowledged pitfall. Ideally, assays need to be adapted to and validated for each matrix. In routine laboratory practice, however, processing different matrices are not always practical, as testing would involve analysis of multiple standard curves and controls depending on the matrix under investigation. A better approach is to organize testing as to limit the number of different assays required. This approach reduces both the time needed for staff training and the costs associated with supplies, standards and instrument maintenance. In this context, an assay was developed based on automated solid-phase extraction (SPE) followed by gas chromatography coupled with tandem mass spectrometry (GC -MS-MS) for the quantification of five different compounds [caffeine, cyamemazine, meprobamate, morphine and 6-monoacetylmorphine (6-MAM)] with heterogeneous physicochemical properties representative of the kinds of drugs encountered in real-life forensic toxicology (Table I ). The SPE protocol proved effective in removing interference and was more reproducible than multistep manual liquid -liquid extraction. Moreover, SPE can be automated, which is important in view of the large number of samples to be processed in validation protocols and in routine practice. Liquid chromatography coupled with tandem mass spectrometry is prone to matrix effects that are difficult to control in postmortem toxicology, especially with complex samples (6); GC -MS-MS using labeled isotopes as internal standards (ISs) and matrix-matched calibration, in contrast, showed well-adapted performance. The assay was validated in 11 biological matrices [blood, urine, bile, vitreous humor (VH), liver, kidney, lung, skeletal muscle, brain, adipose tissue (AT) and bone marrow (BM)] following a cross-validation plan in compliance with FDA guidelines (7) .
The assay was first applied to real samples obtained from a human autopsy. Secondly, it was assessed as a standard process for further development of targeted analysis and screening. For this purpose, an extended application test evaluated the performance of the automated SPE protocol, without modification, in 12 drugs frequently encountered in forensic toxicology (alimemazine, alprazolam, amitriptyline, citalopram, cocaine, diazepam, levomepromazine, nordazepam, tramadol, venlafaxine, pentobarbital and phenobarbital) in blood, BM and lung samples.
The present study reports a validated GC -MS-MS procedure with an automated SPE protocol to quantify five drugs of forensic interest in 11 biological matrices. The interest of the finding is illustrated by two applications: analysis of human samples from a real autopsy case and assessment of the protocol as a starter set for the development of further analytical tools.
Materials and Methods

Standards and reagents
Certified stock solutions of morphine, morphine-d 3 , cyamemazine, 6-MAM, 6-MAM-d 3 , meprobamate and meprobamate-d 3 were purchased from LGC Standards (Molsheim, France); caffeine and 13 C 3 -caffeine powders from Merck (Fontenay-sousBois, France) and Isotec (Miamisburg, OH, USA), respectively; N, O-bis(trimethylsilyl)trifluoroacetamide with 1% trimethylchlorosilane (BSTFA/TMCS) from LGC Standards; cyamemazined 5 from Alsachim (Illkirch-Graffenstaden, France); water, n-hexane, methanol, dichloromethane, hydrochloric acid (HCl, 1 M), sodium hydroxide (NaOH, 1 M) and ammonium hydroxide (NH 4 OH, 1 M) from VWR (Fontenay-sous-Bois, France); acetonitrile, ethyl acetate and ethanol absolute from Carlo Erba (Val de Reuil, France) and sodium dihydrogen phosphate (NaH 2 PO 4 ) was supplied by Merck.
Deuterated analogs were used as ISs. A mixture of the five ISs was prepared by dilution in methanol to obtain the following concentrations in fluids (ng/mL) or tissues (ng/g): meprobamated 3 , 1,000 ng/mL(ng/g); 13 C 3 -caffeine, 500 ng/mL(ng/g); and morphine-d 3 , 6-MAM-d 3 and cyamemazine-d 6 , 200 ng/mL(ng/g). This working solution was stored at 2208C. For calibration standards and quality controls (QCs), a mixture of the five compounds of interest was prepared at the following concentrations: meprobamate, 100 ng/mL; caffeine, 50 ng/mL; and morphine, 6-MAM and cyamemazine, 12.5 ng/mL. Different dilutions were made to obtain the appropriate concentrations.
Samples
Specimens
Biological fluids (blood, urine, VH and bile) and tissues (lung, kidney, brain, liver, muscle, AT and BM) from rabbits were pooled and used for the development, validation and extended application phases of the study. They were obtained from animal experiments performed in strict accordance with established guidelines for animal care, with the approval of the Animal Ethics Committee (Lyon, France). For practical assessment, the assay was applied in samples collected during a forensic autopsy. The victim, a French national on holiday in Africa, had been found dead in his hotel; after embalmment, the body was brought back to France, where the prosecutor asked for a forensic autopsy. Samples of VH, blood, urine, bile, liver, kidney, lung, AT and brain were collected.
Sample pretreatment
For tissues, samples of 200 + 5 mg (lung, kidney, liver, muscle and BM) or 500 + 10 mg (AT and brain) were cut thinly with scissors and homogenized in 2 mL of phosphate buffer (NaH 2 PO 4 , pH 7, 0.5 M). For biological fluids (bile, blood, urine and VH), 200 mL of samples were homogenized in the same buffer as tissues. ISs were added to all matrices. After 10 min mechanical shaking, the mixture was centrifuged (10 min, 1,400Â g). The supernatant was collected and centrifuged a second time (10 min, 1,400Â g) before submission to the SPE procedure.
Solid-phase extraction Automated SPE used the Gx-271 ASPEC (Gilson, Inc., Middleton, WI, USA). The SPE columns (Strata TM X-C; Phenomenex, Le Peck, France; 200 mg, 3 mL capacity) were conditioned with 4 mL of methanol, followed by 4 mL of phosphate buffer before sample loading. The columns were rinsed with 4 mL of acidified water (HCl 1 M adjusted to pH 4 with water), followed by 2 mL of methanol : water mixture (25 : 75, v/v). The analytes were then eluted in two distinct fractions, collected separately and analyzed as described below. Meprobamate and caffeine were eluted first using 2 mL of methanol. The eluate was then evaporated to dryness at 608C under airstream. The residue was reconstituted in 100 mL of deionized water plus 1 mL of ethanol and washed by addition of n-hexane (4 mL). The mixture was vortex-mixed for 30 s and centrifuged for 5 min at 3,000Â g. The lower ethanolic layer was removed, evaporated to dryness at 508C and reconstituted in 40 mL of ethyl acetate. One microliter was injected into the GC -MS-MS system using Method 1 (below).
Morphine, 6-MAM and cyamemazine were eluted in the second elution step using 4 mL of acetonitrile : dichloromethane mixture (50 : 50, v/v) with 5% NH 4 OH. The extract was evaporated to dryness and derived with 25 mL of BSTFA/TMCS for 20 min at 808C. Two microliters were injected into the GC -MS-MS system using Method 2 (below).
Gas chromatography coupled with tandem mass spectrometry The eluates were analyzed using two different methods: Method 1 for meprobamate and caffeine and Method 2 for morphine, 6-MAM and cyamemazine.
Gas chromatography
Gas chromatography was performed on a 7890A GC system (Agilent, Santa Clara, CA, USA) equipped with a 7693 Autosampler (Agilent). For both methods, separation was carried out on a HP-5MS capillary column (30 m length Â 0.250 mm I.D. Â 0.25 mm film thickness) with helium as carrier gas at a constant flow of 1 mL/min. Injection was performed in splitless mode at an injection temperature of 2608C. The transfer line was maintained at 3108C. A specific temperature gradient was used for each method. For Method 1, the initial oven temperature was maintained at 1008C for 1 min, increased at a rate of 208C/ min to 2008C and maintained for 3 min, and finally increased at a rate of 508C/min to 3008C. The final temperature was maintained for 3 min. For Method 2, the temperature was maintained at 1208C for 1 min and increased at a rate of 508C/min to 2808C and maintained for 4 min, and finally increased at a rate of 508C/min to 3008C. The final temperature was maintained at 3008C for 3 min. Methods 1 and 2 had total runtimes of 14.0 and 11.6 min, respectively.
Tandem mass spectrometric conditions GC -MS-MS analysis was acquired using a 7000 triple quadrupole mass spectrometer (Agilent) in positive electronic ionization mode. Ion source temperature was set at 2308C and ionization energy at 70 eV. The collision gas was nitrogen (flow rate, 1.5 mL/min) with helium quench (flow rate, 2.25 mL/min) acquisition performed in multiple reaction monitoring mode. The transitions were chosen according to selectivity and abundance and so as to maximize signal-to-noise (S/N) ratio in the matrix extracts. One transition per compound was used for quantitation, and two transitions as qualifiers, except for morphine-d 3 (only one qualifier). Retention time and MS parameters are outlined in Table II .
Acceptance criteria for compound identification
The compound identification criteria were as follows: for chromatographic peaks, observed retention time differing by not more than +0.1 min from that of the highest calibration standard, prepared and analyzed contemporaneously; for mass spectrometry, qualifier ions ratio differing by not .25% from that of the highest calibration standard. These identification criteria were automatically assessed by the MassHunter Workstation software for quantitative analysis for QQQ (version B.05.00 SP02; Agilent Technologies).
Validation procedure
The validation protocol has been previously described (8) . The validation parameters and all modifications are detailed below.
General pattern BM is a heterogeneous tissue composed of hematopoietic marrow (60% hematopoietic cells) and fatty marrow (95% adipocytes) in variable proportions; this highly variable lipid, water and protein composition (9) makes it one of the most complex matrices to analyze, and it was therefore chosen for full validation of the present assay: linearity, lower limit of quantification (LLOQ), dilution, within-and between-day accuracy and precision, selectivity, extraction recovery (ER) and stability on autosampler over a period of 3 days. Partial validation was performed for the other 10 matrices: linearity, LLOQ, ER, selectivity and within-day accuracy and precision, assessed in 1 day.
Linearity
Owing to the difficulty of homogenizing tissue in solution, calibration standards were prepared by mixing tissue with phosphate buffer spiked with the analytes of interest at five concentration levels. To simplify the procedure, fluid samples (bile, blood, VH and blood) all underwent the same sample preparation process. Two milliliters of the spiked buffer were added to the blank samples to obtain five calibration standards ranging from 100 to 4,000 ng/mL(ng/g) for meprobamate, 50 to 2,000 ng/mL(ng/g) for caffeine and 12.5 to 500 ng/mL(ng/g) for morphine, 6-MAM and cyamemazine. Calibration curves were established by linear least squares regression, using the MassHunter Workstation software for quantitative analysis for QQQ. Curves were based on peak area ratio (analyte/IS) as a function of analyte concentration. The bestfitting calibration model was chosen for each compound in BM, based on residual plots and the determination coefficient. Both criteria were calculated using the MassHunter Workstation software. The model selected for BM was applied to the 10 remaining matrices.
Within-and between-day accuracy and precision For full validation on BM, five iterative determinations were performed on three different days of one low QC (midpoint of the two lowest calibration standards) and one high QC (midpoint of the two highest calibration standards). Concentrations were, respectively, 300 and 3,000 ng/mL(ng/g) for meprobamate, 150 and 1,500 ng/mL(ng/g) for caffeine and 37.5 and 375 ng/mL (ng/g) for morphine, 6-MAM and cyamemazine. Within-and between-run precision were calculated as previously described (8) , using the StatView software for Windows, version 5.0 (SAS Institute, Cary, NC, USA). For partial validation on the other matrices, accuracy and precision were calculated at the same QC level using five iterative determinations. According to the FDA Guidance for Industry -Bioanalytical Method Validation (7), accuracy is required to be between 85 and 115% and precision ,15%.
LLOQ and assessment for extended concentration range An LLOQ was estimated, in a preliminary study on extracted blank BM samples (n ¼ 5), as the concentration corresponding to an S/N ratio of 10 (data not shown). For meprobamate, an LLOQ of 100 ng/g was chosen, much higher than the sensitivity of the assay, in order to correspond to concentrations usually found in forensic cases in our experience. Results were then evaluated according to the Guidance for Bioanalytical Method Validation (7): at this point, accuracy should be 80 -120% and precision ,20% on five iterative determinations. The LLOQ corresponds to the lowest calibration curve concentration. The upper limit of quantification (ULOQ) was set according to the LLOQ in order to favor quantification of low concentrations. A dynamic range with a ratio of 40 between ULOQ and LLOQ was used. A 1/10th procedure dilution was validated for concentrations above the ULOQ: BM was spiked with 20,000 ng/mL(ng/g) for meprobamate, 10,000 ng/mL(ng/g) for caffeine and 2,500 ng/mL(ng/g) for morphine, 6-MAM and cyamemazine. The assay was modified as follows: the IS concentration was 10-fold higher than in the classic procedure, and only 10% of each eluate was collected and then analyzed [i.e., 200 mL of the methanol eluate and 400 mL of the second eluate (acetonitrile : dichloromethane (50 : 50, v/v) with 5% NH 4 OH)].
Selectivity, ER and autosampler stability Selectivity was assessed by analyzing six blank samples of each matrix. ER was assessed for each matrix and each compound, at two levels in three replicates. Low-level concentrations were: 300 ng/mL(ng/g) for meprobamate, 150 ng/mL(ng/g) for caffeine and 37.5 ng/mL(ng/g) for morphine, 6-MAM and cyamemazine; high-level concentrations were: 3,000 ng/mL(ng/g) for meprobamate, 1,500 ng/mL(ng/g) for caffeine and 375 ng/mL(ng/g) for morphine, 6-MAM and cyamemazine. Blank matrices were spiked with ISs before extraction. The ratios of the relative responses (analyte/IS, expressed as chromatographic peak area) obtained by spiking the matrices with analytes before and after extraction were compared. Autosampler stability at 258C was tested by reanalyzing sample extracts 72 h after the first analysis and reevaluating accuracy and precision.
Extended application
Blank matrices (blood, BM and lung) were spiked with alimemazine 20 ng/mL(ng/g), alprazolam 100 ng/mL(ng/g), amitriptyline 100 ng/mL(ng/g), citalopram 20 ng/mL(ng/g), cocaine 10 ng/mL(ng/g), diazepam 10 ng/mL(ng/g), levomepromazine 20 ng/mL(ng/g), nordazepam 50 ng/mL(ng/g), tramadol 100 ng/mL(ng/g), venlafaxine 20 ng/mL(ng/g), pentobarbital 100 ng/mL(ng/g) and phenobarbital 500 ng/mL(ng/g). Each matrix was prepared, in triplicate (n ¼ 3), as described in the 'Sample pretreatment' section (see above), without any modification. Each eluate was analyzed by GC -MS-MS without and after derivatization in 25 mL of BSTFA/TMCS for 20 min at 808C. The GC -MS-MS conditions described above were modified as follows: the transfer line was maintained at 3208C, and initial oven temperature at 908C for 1 min, increased at a rate of 208C/min to 2008C, then at a rate of 158C/min to 3008C and maintained 16 min (total run time, 29.2 min). Retention time and mass parameters are presented in Table III . The S/N ratios were calculated for each compound, using the MassHunter software according to the root mean square algorithm. Noise was assessed for a period of 6 s just before peak.
Results and discussion
Analytic process
The SPE sorbent phase was chosen according to the physicochemical properties of the analytes of interest (Table I) . A polymeric sorbent containing a strong cation-exchange functional group, Strata X-C, was chosen for its ability to isolate and purify basic compounds such as morphine, 6-MAM and cyamemazine from biological matrices. Moreover, the large particles (mean, 33 mm; range, 28 -34) and pores of the sorbent (75 -91 Å ) allowed samples with varying degrees of viscosity to be analyzed. Despite the sorbent's high porosity, two centrifugation steps were systematically applied before performing SPE. Morphine and 6-MAM required derivatization with BSTFA/TMCS in order to be analyzed by GC -MS-MS while meprobamate is degraded during this derivatization reaction. Because two distinct extractions cost more in terms of sample quantity, time and money, extraction was optimized to obtain two eluates analyzed separately from a single sample. The first step, with methanol, eluted acid and neutral compounds, while the second, using an acetonitrile : dichloromethane mixture (50 : 50, v/v) with 5% NH 4 OH, eluted the basic compounds. Under these conditions, caffeine and meprobamate were extracted in the first elution and morphine, 6-MAM and cyamemazine in the second. A hexane wash step was performed on the first eluate to remove lipid residue, which could have interfered with analysis. The hexane wash was initially included in order to "clean-up" various postmortem samples by eliminating interference from lipid matrices (e.g., BM, AT, brain) or from postmortem degradation. If the protocol is used on cleaner matrices such as blood or VH, this second centrifugation and lipid removal step could, after assessment, be found superfluous.
Validation procedure
As in the previous study (8) , full validation was performed on BM, the most complex matrix, and partial validation on the other 10 matrices. Transition: precursor ion ! product ion.
Linearity
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provided the best calibration models. Linear regression determination coefficients (r 2 ) were !0.990 for all compounds in each matrix. Between-day validation of the calibration curves was satisfactory for all molecules (Table IV) : precision was ,15% and accuracy 85 -115%.
Within-and between-day precision and accuracy
Within-and between-day precision and accuracy were estimated at two levels (low and high QC) in BM. None of the analytes demonstrated precision .15% or accuracy outside of the 85 -115% range (Table V) . Validation on the other matrices (Table VI) showed accuracy of 80 -120% for all analytes, except for cyamemazine in kidney where accuracy was 135% at the high-QC level. Precision was ,15% for all parameters, except for 6-MAM and morphine in blood where it was slightly .15% (15.2 and 15.1%, respectively).
Limits of quantification
The LLOQ corresponds to the concentration of the lowest calibration standard. At that point, accuracy and precision were determined on five iterative runs (Table V for BM and Table VI for the other matrices). Precision and accuracy at the LLOQ in BM were, respectively, ,20% and between 80 and 120%, for all molecules. In the matrices used for partial validation, accuracy at the LLOQ was slightly above the limit of 120% for morphine in muscle, but failed for meprobamate in kidney (138.6%) and cyamemazine in kidney (148.6%). For the latter, quantification of low QC showed accuracy and precision ,15%. A low-QC level of 300 ng/g for meprobamate and 37.5 ng/g for cyamemazine should, therefore, be used as the LLOQ. These limits were still sufficient for application in postmortem toxicology in the light of the usual blood concentrations for the two molecules. The LLOQ is consistent with published GC -MS and GC -MS-MS methods for tissue opiate analysis (10 -14) . The assay used in Goldberger et al.'s study (15) of heroin distribution in various tissues and fluids was more sensitive than the present assay in blood: 1.0 ng/mL for heroin, 6-MAM and morphine, but with no data for tissue analysis. The assay reported by da Fonseca et al. (16) gave an LLOQ of 4 ng/mL in human plasma for cyamemazine, lower than in the present study; however, their assay was dedicated to human plasma analysis, requiring only limited preparation but incompatible with complex or putrefied samples. As suggested above, some of the purification steps of the present protocol, such as lipid removal or second centrifugation, could be skipped for less complex matrices, thereby enhancing efficiency.
Selectivity and ER
Sixty-six blank samples were analyzed: six per matrix, collected from five human autopsy samples and one rabbit. None gave positive results according to the identification criteria. ER in BM was .40% for caffeine and meprobamate, the molecules eluted in the first elution. The molecules from the second elution, cyamemazine, morphine and 6-MAM, showed ER ,20%. This tendency can be extended to other tissues, since ER for morphine, 6-MAM and cyamemazine in tissue was less than for meprobamate and caffeine. The lipophilicity of morphine, 6-MAM and especially cyamemazine increases possible matrix interactions, which may decrease the amount of analyte retained on the SPE sorbent. This hypothesis seems to be confirmed by the ER values found for cyamemazine, morphine and 6-MAM in aqueous samples (blood, urine, bile and VH), which were higher than in BM and similar to those for caffeine and meprobamate. However, the lipid nature of the sample cannot fully explain this difference, as demonstrated by the relatively high ER for cyamemazine in AT (38.7%) compared with less lipid tissue such as muscle (10.2%) or lung (13.2%).
Other validation parameters
Sample dilution (1/10), assessed only in the full validation protocol applied on BM, satisfied the accuracy and precision criteria (Table V) . Seventy-two-hour stability on autosampler was assessed using low and high QCs. For both QCs, accuracy and precision were ,15% for both underivatized and trimethylsilyl (TMS)-derivatized analytes (Table V) . In practice, a 72-h interval usually allows any GC -MS-MS malfunction to be resolved and prevents loss of samples.
Application
Toxicological analysis was performed on the samples collected from autopsy after the embalmment process.
A screening step performed on urine detected morphine. The present protocol was then applied to quantify morphine and 6-MAM in each available sample. The chromatograms of morphine and 6-MAM and the concentrations obtained for the 10 matrices are reported in Figure 1 . The morphine concentration ratio of 25 between VH to femoral blood was higher than all 70 observations reported by Rees et al. (17) , where it ranged from 0.09 to 5.2 for free morphine [mean ¼ 0.99, standard deviation (SD) ¼ 0.93]. This difference suggests dilution or degradation consecutive to embalmment. The presence of 6-MAM in VH, urine, bile, lung and muscle indicated heroin consumption. The lack of free 6-MAM in blood could be interpreted as delayed death (.3 h) (17, 18) ; however, the presence of 6-MAM in blood at time of death could not be formally ruled out in this context of embalmment. The significant concentration of 6-MAM in VH (27.3 ng/mL), even though it is known that this metabolite can be detected for a longer period than in blood (17) , is in favor of the presence of 6-MAM in blood at time of death. Morphine and 6-MAM were also detected in certain other matrices, at concentrations consistent with previous data for heroinrelated deaths (15, 19) . Taking into account the concentrations of 6-MAM and morphine in the various samples and the embalmment treatment, results combined to suggest heroin-related death.
Extended application
Limiting the number of assay protocols used in a laboratory is beneficial from both practical and economic points of view.
The present sample preparation was therefore assessed in blood, BM and lung for the analysis of 12 further compounds of forensic interest exhibiting varied physicochemical properties. Peak areas and S/N ratios are reported in Table VII . Tramadol, venlafaxine and nordazepam were analyzed as their TMS derivatives. All spiked analytes were detected in all three matrices. Concentrations were consistent with therapeutic levels. In most cases, the difference in S/N ratio between elutions 1 and 2 was due to variation in signal rather than in noise. For example, in the blood pentobarbital assay, the 20-fold S/N difference was directly related to an increase in signal. Analysis of barbiturate drugs ( phenobarbital and pentobarbital) showed poor reproducibility, as demonstrated by the wide standard deviation observed on three replicates.
The compounds with the highest pKa (tramadol, venlafaxine, amitriptyline, cocaine, alimemazine, citalopram and levomepromazine) were detected only in the second elution (basified acetonitrile/dichloromethane). Benzodiazepines and barbiturates were found in both elutions, in matrix-dependent proportions. In blood, nordazepam and diazepam were mainly eluted in methanol fraction (Elution 1), whereas in BM, the most lipid sample, they were found mostly in the second elution. Phenobarbital and pentobarbital ( pKa 7.2 and 7.9, respectively) were mainly Quantification of Five Drugs in 11 Matrices by SPE GC-MS eluted in methanol fraction (Elution 1) in all samples. All these results are consistent with the interaction mechanism of a mixed-mode cation exchanger SPE sorbent. Acidic, neutral and weak basic drugs, such as benzodiazepines and barbiturates, are retained on the cartridge thanks to hydrophobic interaction in their neutral form or due to weak ionic interaction. These compounds are incompletely eluted with methanol and are thus detected in both elutes. If the assay is to be used specifically for analysis of such compounds, a less polar solvent, such as ethyl acetate or dichloromethane, could be used to achieve a more efficient elution in a single step. Basic compounds (alimemazine, amitriptyline, citalopram, cocaine, levomepromazine, tramadol and venlafaxine), which are mainly in their cationic form in the phosphate buffer pH 7, are retained on sorbent due to strong ionic interaction. These analytes are eluted in the second elution step [acetonitrile : dichloromethane (50 : 50, v/v) with 5% NH 4 OH]. For specific analysis of such basic compounds, the sample preparation protocol could be performed without modification and the first elution with methanol could be useful as a clean-up step. Conclusion GC -MS-MS coupled with an automated SPE protocol was developed for quantification of caffeine, cyamemazine, meprobamate, morphine and 6-MAM in 11 biological matrices. The performance of this assay allows application in forensic toxicology or pharmacokinetic studies. The extraction protocol can be used for targeted analysis of various basic drugs and, with optimization, for other drugs or screening procedures in complex matrices. It could thus be an interesting starting set for further development for laboratories seeking to optimize their activity. 
